Developing informatics tools for optimized MRS for brain cancer research

项目摘要/摘要 该项目建议开发自动、实时、单体素磁共振的方法 脑肿瘤的波谱(MRS)，将这些方法与临床MRI系统相结合，评估它们的 性能，并将它们作为开源工具分发给研究社区。MRS可以提供代谢 为评估肿瘤表型和治疗反应提供无创性信息。单体素MRS 方法提供了最好的质量和最可靠的数据，但要求扫描仪操作员具有很高的技能 水平和专业知识，以产生高质量的结果。在这两项收购中需要这位专家参与 而处理仍然是将MRS方法转换到临床研究站点的关键障碍，而不是 光谱学专家和临床实践。该项目的第一部分是开发一种3D体素的方法 使用图像引导进行定位，将该方法与临床磁共振系统相结合，并评估其 性能。在第二部分，我们将自动化我们的先进的MRS方法。在第三部分中，我们将创建 特定于获得的MRS数据的实时、自动量化工具，将提供临床上可解释的 结果。我们确定了合作者、脑癌研究人员和临床医生，他们将是早期采用者和 我们工具的测试者。该项目的成功完成将提高数据的稳健性和质量， 消除了在扫描时需要专家交互的情况，并支持在多个 现场临床试验和临床实践。

PROJECT SUMMARY/ABSTRACT This project proposes to develop methods for automated, real-time, single-voxel magnetic resonance spectroscopy (MRS) in brain tumors, integrate these methods with a clinical MRI system, evaluate their performance, and distribute them as open-source tools to the research community. MRS can provide metabolic information noninvasively for assessment of tumor phenotype and therapeutic response. Single-voxel MRS methods provide the best quality and most reliable data, but require the scanner operator to have a high skill level and expertise to produce good quality results. The need for this expert involvement in both acquisition and processing remains a critical barrier to the translation of MRS methods to clinical research sites without spectroscopy experts and to clinical practice. The first part of this project is to develop a method for 3D voxel placement using image guidance, integrate this method with a clinical MR system, and evaluate its performance. In the second part, we will automate our advanced MRS methods. In the third part, we will create real-time, automatic quantification tool specific to the obtained MRS data that will provide clinically interpretable results. We identified collaborators, the brain cancer researchers and clinicians, who will be early adopters and beta-testers of our tools. Successful completion of this project will improve data robustness and quality, eliminating the need for the expert interaction at the time of the scan and enabling adoption of MRS in multi- site clinical trials and clinical practice.